Your browser doesn't support javascript.
loading
Use of QSPR Modeling to Characterize In Vitro Binding of Drugs to a Gut-Restricted Polymer.
Brew, Christine Taylor; Blake, James F; Mistry, Anita; Liu, Fengling; Carreno, Diana; Madsen, Deidre; Mu, YongQi; Mayo, Martha; Stahl, Wilhelm; Matthews, David; Maclean, Derek; Harrison, Steve.
Afiliação
  • Brew CT; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA. tbrew@relypsa.com.
  • Blake JF; Computational Chemistry Department, Array BioPharma Inc, Boulder, Colorado, USA.
  • Mistry A; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
  • Liu F; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
  • Carreno D; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
  • Madsen D; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
  • Mu Y; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
  • Mayo M; Clinical Development, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, California, USA.
  • Stahl W; Technical Operations, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, California, USA.
  • Matthews D; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
  • Maclean D; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
  • Harrison S; Research Department, Relypsa, Inc., a Vifor Pharma Group Company, 100 Cardinal Way, Redwood City, California, 94063, USA.
Pharm Res ; 35(4): 89, 2018 Mar 08.
Article em En | MEDLINE | ID: mdl-29520505
ABSTRACT

PURPOSE:

Polymeric drugs, including patiromer (Veltassa®), bind target molecules or ions in the gut, allowing fecal elimination. Non-absorbed insoluble polymers, like patiromer, avoid common systemic drug-drug interactions (DDIs). However, the potential for DDI via polymer binding to orally administered drugs during transit of the gastrointestinal tract remains. Here we elucidate the properties correlated with drug-patiromer binding using quantitative structure-property relationship (QSPR) models.

METHODS:

We selected 28 drugs to evaluate for binding to patiromer in vitro over a range of pH and ionic conditions intended to mimic the gut environment. Using this in vitro data, we developed QSPR models using step-wise linear regression and analyzed over 100 physiochemical drug descriptors.

RESULTS:

Four descriptors emerged that account for ~70% of patiromer-drug binding in vitro the computed surface area of hydrogen bond accepting atoms, ionization potential, electron affinity, and lipophilicity (R 2 = 0.7, Q 2 = 0.6). Further, certain molecular properties are shared by nonbinding, weak, or strong binding compounds.

CONCLUSIONS:

These findings offer insight into drivers of in vitro binding to patiromer and describe a useful approach for assessing potential drug-binding risk of investigational polymeric drugs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polímeros / Relação Quantitativa Estrutura-Atividade / Pesquisa Farmacêutica / Modelos Biológicos Tipo de estudo: Evaluation_studies / Prognostic_studies Idioma: En Revista: Pharm Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polímeros / Relação Quantitativa Estrutura-Atividade / Pesquisa Farmacêutica / Modelos Biológicos Tipo de estudo: Evaluation_studies / Prognostic_studies Idioma: En Revista: Pharm Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos